COMPANY PROFILE // THE 014 REPORT
Sionna Therapeutics, Inc.
SION (Nasdaq)
Assembled from 2 government sources in 0.1 s
FLAGS · DISCLOSURE · SUMMARY
Missing or hidden
No flag from the records checked. 25 of 26 lists and sources checked came back clear (panel below).
✓ SEC filings✓ State registrationpossible match✗ LEI✗ SAM registration✗ IRS return✗ Website✗ Lobbying registration
No LEI, no SAM registration, no IRS return, no website, no lobbying registration on record.
Sionna Therapeutics, Inc. is an SEC-registered operating company in pharmaceutical preparations, incorporated in DE, based in Waltham, MA; listed as SION (Nasdaq).[source] It has filed 82 documents with the SEC in the last 12 months; the latest is Form 10-Q, filed 2026-11-10.[source] Its largest institutional holders on 13F filings are RA CAPITAL MANAGEMENT, L.P., TPG GP A, LLC, VIKING GLOBAL INVESTORS LP (as of 2026-06-30).[source] 25 of 26 lists and sources checked came back clear; the rest are listed with their result.[source]
- red0
- amber0
- info0
- RA CAPITAL MANAGEMENT, L.P.$435.7M
- TPG GP A, LLC$285.7M
- VIKING GLOBAL INVESTORS LP$140.6M
- Atlas Venture Life Science Advisors, LLC$131.8M
- ORBIMED ADVISORS LLC$112.4M
- ENAVATE SCIENCES GP, LLC$109.0M
- ADAGE CAPITAL PARTNERS GP, L.L.C.$70.4M
- BlackRock, Inc.$64.9M
RECORD · WEB
Ask about this entity
Answers come from this 014 first; every line is marked RECORD (our record, linked) or WEB (a web page, credited and linked).
PEOPLE · COUNSEL · LINKS
Leadership, advisers and links
Officers and directors (Forms 3, 4, 5)
- Beer Caroline Stark · Chief Business Officer (Officer) · latest Form 4 2026-01-06 · filing · LinkedIn search
- Cloonan Michael · President & CEO (Director,Officer) · latest Form 4 2026-01-06 · filing · LinkedIn search
- Fitzpatrick Jennifer · Chief Legal Officer (Officer) · latest Form 4 2026-03-06 · filing · LinkedIn search
- McKee Charlotte · Chief Medical Officer (Officer) · latest Form 4 2026-01-06 · filing · LinkedIn search
- Ridloff Elena · CFO (Officer) · latest Form 4 2026-01-06 · filing · LinkedIn search
- Booth Bruce · Director · latest Form 4 2025-10-21 · filing · LinkedIn search
- Clancy Paul J · Director · latest Form 4 2025-06-16 · filing · LinkedIn search
- Fleming Harold Edward · Director · latest Form 4 2025-06-16 · filing · LinkedIn search
- Kolchinsky Peter · Director,10% owner · latest Form 4 2025-11-24 · filing · LinkedIn search
- ORBIMED ADVISORS LLC · Director · latest Form 4 2026-02-04 · filing · LinkedIn search
- OrbiMed Capital GP VIII LLC · Director · latest Form 4 2026-02-04 · filing · LinkedIn search
- RA CAPITAL MANAGEMENT, L.P. · Director,10% owner · latest Form 4 2025-11-24 · filing · LinkedIn search
As reported to the SEC by the insiders themselves; SEC insider transactions data sets (Forms 3, 4, 5): 2026q1, 2025q4, 2025q3, 2025q2.
Legal counsel, as publicly named
- GOODWIN PROCTER LLP · Exhibit 5.1 legal opinion, S-8 filed 2026-03-02
EVERY LIST AND SOURCE · DATED
Checked and clear
26 lists and sources checked: 25 CLEAR, 1 POSSIBLE MATCH, 0 MATCH. Screening lists are checked when this 014 is built; the enforcement and registry sources at the last company-engine build. Each date is the date of that check.
EVERY IDENTIFIER · LINKED
ID crosswalk
| Identifier | Value | Record |
|---|---|---|
| SEC CIK | 0002036042 | source |
| EIN | 00-0000000 | source |
| Business address (SEC) | 21 HICKORY DRIVE, SUITE 500, WALTHAM, MA, 02451 | source |
Does not exist in the records we hold: LEI, UEI, NY DOS ID, FDIC certificate.
EACH FEEDS WATCH
Dates coming up
- 2027-03-31 · in 131 days · Next 10-K due (period ended 2026-12-31; Non-accelerated filer<br>Smaller reporting company<br>Emerging growth company) (computed from the fiscal year end and filer status)
- 2027-05-15 · in 176 days · Next 10-Q due (period ended 2027-03-31; Non-accelerated filer<br>Smaller reporting company<br>Emerging growth company) (computed from the fiscal year end and filer status)
PEERS BY SIC CODE
Industry context
SIC 2834 (pharmaceutical preparations): 568 companies in our records share this code.
federal dollars
lobbying filings
SEC filings in 12 months
flags
Peers, each with its 014
- PFIZER INC · 124 SEC filings in 12 months · $25.74B federal (possible match)
- Merck & Co., Inc. · 150 SEC filings in 12 months · $13.51B federal (possible match)
- ABBOTT LABORATORIES · 118 SEC filings in 12 months · 1 flag · $2.64B federal (possible match)
- ASTRAZENECA PLC · 140 SEC filings in 12 months · $602.8M federal (possible match)
- TEVA PHARMACEUTICAL INDUSTRIES LTD · 168 SEC filings in 12 months · $77.6M federal (possible match)
- NOVARTIS AG · 34 SEC filings in 12 months · $41.9M federal (possible match)
- Spero Therapeutics, Inc. · 41 SEC filings in 12 months · 4 flags · $39.5M federal (possible match)
- Grifols SA · 18 SEC filings in 12 months · $22.5M federal (possible match)
- SCYNEXIS INC · 54 SEC filings in 12 months · 3 flags · $18.5M federal (possible match)
- Ensysce Biosciences, Inc. · 45 SEC filings in 12 months · 3 flags · $15.1M federal (possible match)
- UNITED THERAPEUTICS Corp · 454 SEC filings in 12 months · 2 flags · $6.8M federal (possible match)
- Zoetis Inc. · 144 SEC filings in 12 months · 1 flag · $6.7M federal (possible match)
SHARED PEOPLE · SHARED ADDRESS
Network neighbours
Shared directors and officers
- Kymera Therapeutics, Inc. · Ridloff Elena
- Kymera Therapeutics, Inc. · Booth Bruce
- INCYTE CORP · Clancy Paul J
- Xilio Therapeutics, Inc. · Clancy Paul J
- CRISPR Therapeutics AG · Fleming Harold Edward
- Upstream Bio, Inc. · Fleming Harold Edward
- Corvus Pharmaceuticals, Inc. · ORBIMED ADVISORS LLC
- Keros Therapeutics, Inc. · ORBIMED ADVISORS LLC
- Shattuck Labs, Inc. · ORBIMED ADVISORS LLC
- Edgewise Therapeutics, Inc. · ORBIMED ADVISORS LLC
- Compass Therapeutics, Inc. · ORBIMED ADVISORS LLC
- ImageneBio, Inc. · ORBIMED ADVISORS LLC
- Climb Bio, Inc. · RA Capital Nexus Fund III, L.P.
- SpyGlass Pharma, Inc. · RA Capital Nexus Fund III, L.P.
- Artiva Biotherapeutics, Inc. · RA Capital Nexus Fund III, L.P.
EVERY SOURCE · NEWEST FIRST
One timeline
- 2026-11-10 filing Quarterly report (10-Q) · SEC EDGAR
- 2026-11-10 filing 8-K items 2.02,9.01 · SEC EDGAR
- 2026-09-21 filing SCHEDULE 13D/A · SEC EDGAR
- 2026-09-17 filing 144 · SEC EDGAR
- 2026-09-14 officer change 8-K items 2.05,5.02,8.01,9.01 · SEC EDGAR
- 2026-08-10 filing 8-K items 8.01,9.01 · SEC EDGAR
- 2026-08-06 filing Quarterly report (10-Q) · SEC EDGAR
- 2026-08-06 filing 8-K items 2.02,9.01 · SEC EDGAR
- 2026-07-06 filing 144 · SEC EDGAR
- 2026-06-18 filing 8-K items 5.07 · SEC EDGAR
- 2026-06-01 filing 144/A · SEC EDGAR
- 2026-05-29 filing 144 · SEC EDGAR
- 2026-05-12 filing Quarterly report (10-Q) · SEC EDGAR
- 2026-05-12 filing 8-K items 2.02,9.01 · SEC EDGAR
- 2026-04-27 filing ARS · SEC EDGAR
- 2026-04-27 filing DEFA14A · SEC EDGAR
- 2026-04-27 filing Proxy statement · SEC EDGAR
- 2026-04-20 filing SCHEDULE 13D/A · SEC EDGAR
- 2026-03-05 filing 144 · SEC EDGAR
- 2026-03-02 filing S-8 · SEC EDGAR
- 2026-03-02 filing S-3ASR · SEC EDGAR
- 2026-03-02 filing Annual report (10-K) · SEC EDGAR
- 2026-03-02 filing 8-K items 2.02,9.01 · SEC EDGAR
- 2026-01-22 filing 144 · SEC EDGAR
- 2026-01-22 filing 144 · SEC EDGAR
- 2026-01-06 insider First Form 3/4/5 on record for McKee Charlotte (Chief Medical Officer) · SEC Forms 3/4/5
- 2025-12-05 filing 144 · SEC EDGAR
- 2025-11-26 insider First Form 3/4/5 on record for ORBIMED ADVISORS LLC (Director) · SEC Forms 3/4/5
- 2025-11-26 insider First Form 3/4/5 on record for OrbiMed Capital GP VIII LLC (Director) · SEC Forms 3/4/5
- 2025-11-24 filing 144 · SEC EDGAR
118 earlier entries
- 2025-11-21 filing 144
- 2025-11-21 filing 144
- 2025-11-21 filing 144
- 2025-11-21 filing 144
- 2025-11-20 filing 144
- 2025-11-20 filing 144
- 2025-11-20 filing 144
- 2025-11-20 filing 144
- 2025-11-19 filing 144
- 2025-11-19 filing 144
- 2025-11-19 filing 144
- 2025-11-19 filing 144
- 2025-11-18 filing 144
- 2025-11-18 filing 144
- 2025-11-18 filing 144
- 2025-11-18 filing 144
- 2025-11-17 filing 144
- 2025-11-17 filing 144
- 2025-11-17 filing 144
- 2025-11-17 filing 144
- 2025-11-07 filing SCHEDULE 13D/A
- 2025-11-05 filing Quarterly report (10-Q)
- 2025-11-05 filing 8-K items 2.02,9.01
- 2025-10-28 filing 144
- 2025-10-28 filing 144
- 2025-10-28 filing 144
- 2025-10-28 filing 144
- 2025-10-24 filing 144
- 2025-10-24 filing 144
- 2025-10-24 filing 144
- 2025-10-24 filing 144
- 2025-10-21 filing 144
- 2025-10-21 filing 144
- 2025-10-21 filing 144
- 2025-10-20 filing SCHEDULE 13D/A
- 2025-10-20 filing 144
- 2025-10-20 filing 144
- 2025-10-17 filing 144
- 2025-10-17 filing 144
- 2025-10-16 filing 144
- 2025-10-16 filing 144
- 2025-10-16 filing 144
- 2025-10-15 filing 144
- 2025-10-14 filing 144
- 2025-10-14 filing 144
- 2025-10-10 filing 144
- 2025-10-10 filing 144
- 2025-10-06 filing 144
- 2025-10-06 filing 144
- 2025-10-03 filing 144
- 2025-10-03 filing 144
- 2025-10-03 insider First Form 3/4/5 on record for Beer Caroline Stark (Chief Business Officer)
- 2025-10-01 filing 144
- 2025-10-01 filing 144
- 2025-09-30 filing 144
- 2025-09-30 filing 144
- 2025-09-29 filing 144
- 2025-09-29 filing 144
- 2025-09-26 filing 144
- 2025-09-04 filing 144
- 2025-08-26 filing 144
- 2025-08-26 filing 144
- 2025-08-21 insider First Form 3/4/5 on record for Cloonan Michael (President & CEO)
- 2025-08-21 insider First Form 3/4/5 on record for Ridloff Elena (CFO)
- 2025-08-20 filing 144
- 2025-08-20 filing 144
- 2025-08-19 filing 144
- 2025-08-11 filing Quarterly report (10-Q)
- 2025-08-11 filing 8-K items 2.02,9.01
- 2025-06-16 insider First Form 3/4/5 on record for Booth Bruce (Director)
- 2025-06-16 insider First Form 3/4/5 on record for Clancy Paul J (Director)
- 2025-06-16 insider First Form 3/4/5 on record for Fleming Harold Edward (Director)
- 2025-06-16 insider First Form 3/4/5 on record for Kolchinsky Peter (Director,10% owner)
- 2025-06-16 insider First Form 3/4/5 on record for RA CAPITAL MANAGEMENT, L.P. (Director,10% owner)
- 2025-06-16 insider First Form 3/4/5 on record for RA Capital Healthcare Fund LP (Director,10% owner)
- 2025-06-16 insider First Form 3/4/5 on record for RA Capital Nexus Fund III, L.P. (Director)
- 2025-06-16 insider First Form 3/4/5 on record for RA Capital Nexus Fund, L.P. (Director)
- 2025-06-16 insider First Form 3/4/5 on record for Resnick Joshua (Director)
- 2025-06-16 insider First Form 3/4/5 on record for Ruddy Marcella K. (Director)
- 2025-06-16 insider First Form 3/4/5 on record for Shah Rajeev M. (Director,10% owner)
- 2025-06-16 insider First Form 3/4/5 on record for Stelzer Laurie (Director)
- 2025-06-16 insider First Form 3/4/5 on record for Thompson Peter A. (Director)
- 2025-06-16 insider First Form 3/4/5 on record for Viney Joanne L. (Director)
- 2025-06-13 filing 8-K items 5.07
- 2025-06-04 filing 8-K items 7.01,9.01
- 2025-05-12 filing Quarterly report (10-Q)
- 2025-05-12 filing 8-K items 2.02,9.01
- 2025-04-29 filing ARS
- 2025-04-29 filing DEFA14A
- 2025-04-29 filing Proxy statement
- 2025-04-01 insider First Form 3/4/5 on record for Fitzpatrick Jennifer (Chief Legal Officer)
- 2025-03-20 filing Annual report (10-K)
- 2025-03-20 filing 8-K items 2.02,9.01
- 2025-02-18 filing SCHEDULE 13D
- 2025-02-18 filing SCHEDULE 13D
- 2025-02-18 filing SCHEDULE 13D
- 2025-02-18 filing SCHEDULE 13D
- 2025-02-13 filing SCHEDULE 13D
- 2025-02-10 filing 8-K items 5.03,9.01
- 2025-02-07 filing S-8
- 2025-02-07 filing 424B4
- 2025-02-06 filing SEC STAFF LETTER
- 2025-02-06 filing EFFECT
- 2025-02-06 filing S-1MEF
- 2025-02-06 filing CERT
- 2025-02-04 filing 8-A12B
- 2025-02-04 filing CORRESP
- 2025-02-04 filing CORRESP
- 2025-02-03 filing S-1/A
- 2025-01-24 filing CORRESP
- 2025-01-17 filing CORRESP
- 2025-01-17 filing Registration (S-1)
- 2024-12-10 filing UPLOAD
- 2024-11-26 filing DRSLTR
- 2024-11-26 filing DRS/A
- 2024-10-10 filing SEC STAFF LETTER
- 2024-10-10 filing UPLOAD
- 2024-09-12 filing DRS
RENDERED FROM THIS PAGE
Relationship graph
Holders from 13F filings, subsidiaries from the GLEIF tree (by LEI), lobbying firms from LDA (possible match), agencies from USAspending, people from Forms 3/4/5, counsel from Exhibit 5.1, shared boards from Forms 3/4/5.
DATA MOTION // NEWEST FIRSTWhat changed
- 2026-11-10 (within 30 days) 10-Q filed
- 2026-11-10 (within 30 days) 8-K filed: Item 2.02 results of operations; Item 9.01 exhibits
- 2026-09-14 (older) 8-K filed: Item 2.05 exit or disposal costs; Item 5.02 officer or director change; Item 8.01 other event; Item 9.01 exhibits
- 2026-08-10 (older) 8-K filed: Item 8.01 other event; Item 9.01 exhibits
- 2026-08-06 (older) 10-Q filed
- 2026-08-06 (older) 8-K filed: Item 2.02 results of operations; Item 9.01 exhibits
- 2026-06-18 (older) 8-K filed: Item 5.07 shareholder vote
- 2026-05-12 (older) 10-Q filed
Dot rule: red = within 7 days, amber = within 30 days, green = older. Measured against 2026-11-20; the colour is also written out in words.
COUNTS FROM THIS PAGERelationships at a glance
PRICE · FILINGS · POSTS · NEWSMarket & news
- Price
- NASDAQ:SION The chart widget (TradingView) shows the price and the previous session's close. Seraphix publishes no price of its own.
- Open in
Open in…
Price and chart
News
Analyst estimates and earnings
Institutional holders
Short interest
Official social
Each link opens the other site in a new tab, with this company filled in. That site shows its own data under its own terms; Seraphix stores none of it. Seraphix counts clicks per link, nothing about who clicked.
- Financials
- Filed figures: published SEC values, each linked to its filing.
- Official posts
- Links to posts from the company's and agencies' verified accounts: not connected yet.
- News
- Article links (headline, date, link): not connected yet.
EVERY RESOLVED IDENTIFIER1. Identity
3 possible matches held apart, matched by name only, not counted above.
| Identifier | Value | How it was resolved | Source |
|---|---|---|---|
| SEC CIK | 2036042 | id:sec-anchor: the SEC registrant record of this company | SEC EDGAR |
| Ticker / exchange | SION / Nasdaq | SEC company record: ticker and exchange as listed on the SEC company record | SEC EDGAR |
| CUSIP | 829401108 | carried on the SEC-anchored record: listed in the identifiers of sx:sec:0002036042 | SEC EDGAR |
possible match: matched by name only, not merged (1)
Identifiers carried by records that share the company's exact name. Not merged into the identity above.
| Identifier | Value | How it was resolved | Source |
|---|---|---|---|
| EPA FRS id | 110071333461 (SIONNA THERAPEUTICS) | name-exact: exact name match to 'Sionna Therapeutics, Inc.' (no other entity shares the name) | EPA ECHO facilities |
AS FILED · EACH WITH ITS DATE AND FILING2. Filed figures
Key figures (annual filing)
| Figure | Value | Period or as of | Source | Basis | Retrieved | Report |
|---|---|---|---|---|---|---|
| Net income (loss) (fiscal year ended 2025-12-31) | -$75,268,000 | 2025-12-31 | 10-K, XBRL NetIncomeLoss | as filed | 2026-11-20 22:48 UTC | Report an error |
| Total assets (at 2025-12-31) | $325,953,000 | 2025-12-31 | 10-K, XBRL Assets | as filed | 2026-11-20 22:48 UTC | Report an error |
| Stockholders' equity (at 2025-12-31) | $306,833,000 | 2025-12-31 | 10-K, XBRL StockholdersEquity | as filed | 2026-11-20 22:48 UTC | Report an error |
| Cash and cash equivalents (at 2025-12-31) | $58,451,000 | 2025-12-31 | 10-K, XBRL CashAndCashEquivalentsAtCarryingValue | as filed | 2026-11-20 22:48 UTC | Report an error |
Company profile facts (SEC)
| Figure | Value | Period or as of | Source | Basis | Retrieved | Report |
|---|---|---|---|---|---|---|
| SEC entity type | operating | 2026-11-10 | SEC EDGAR company profile | as filed | 2026-11-20 22:48 UTC | Report an error |
| SIC industry | 2834 Pharmaceutical Preparations | 2026-11-10 | SEC EDGAR company profile | as filed | 2026-11-20 22:48 UTC | Report an error |
| State of incorporation | DE | 2026-11-10 | SEC EDGAR company profile | as filed | 2026-11-20 22:48 UTC | Report an error |
| Fiscal year end (MMDD) | 1231 | 2026-11-10 | SEC EDGAR company profile | as filed | 2026-11-20 22:48 UTC | Report an error |
| Business address | 21 HICKORY DRIVE, SUITE 500, WALTHAM, MA, 02451 | 2026-11-10 | SEC EDGAR company profile | as filed | 2026-11-20 22:48 UTC | Report an error |
| Exchanges | Nasdaq | 2026-11-10 | SEC EDGAR company profile | as filed | 2026-11-20 22:48 UTC | Report an error |
Other filed values
| Figure | Value | Period or as of | Source | Basis | Retrieved | Report |
|---|---|---|---|---|---|---|
| Operating cash flow (fiscal year ended 2025-12-31) | -$66,297,000 | 2025-12-31 | 10-K, XBRL NetCashProvidedByUsedInOperatingActivities | as filed | 2026-11-20 22:48 UTC | Report an error |
| Capital expenditures (property, plant and equipment) (fiscal year ended 2025-12-31) | $377,000 | 2025-12-31 | 10-K, XBRL PaymentsToAcquirePropertyPlantAndEquipment | as filed | 2026-11-20 22:48 UTC | Report an error |
| Operating lease liabilities (at 2025-12-31) | $8,677,000 | 2025-12-31 | 10-K, XBRL OperatingLeaseLiability | as filed | 2026-11-20 22:48 UTC | Report an error |
Latest report: 10-Q for the period ended 2026-09-30, filed 2026-11-10 · accession 0001628280-26-072499
| Item | Value | Period | Form | Filed | Accession | Retrieved | Report |
|---|---|---|---|---|---|---|---|
| Net income (loss) | -$32,418,000 | 3 months ended 2026-09-30 | 10-Q | 2026-11-10 | 0001628280-26-072499 | 2026-11-20 22:48 UTC | Report an error |
| Cash and cash equivalents | $83,878,000 | at 2026-09-30 | 10-Q | 2026-11-10 | 0001628280-26-072499 | 2026-11-20 22:48 UTC | Report an error |
Values as filed in XBRL (SEC company facts); quarterly values are the filer's own 3-month figures, never derived.
No estimates: every value is as filed and links to the filing it came from.
Registration: the SEC filer status is under "Company profile facts (SEC)" above. SAM.gov registration status: not held yet.
NEWEST FIRST · EACH LINKS TO ITS FILING3. Registration and filing timeline
- 2026-11-10 Filing 10-Q filed
- 2026-11-10 Filing 8-K filed: Item 2.02 results of operations; Item 9.01 exhibits
- 2026-09-14 Filing 8-K filed: Item 2.05 exit or disposal costs; Item 5.02 officer or director change; Item 8.01 other event; Item 9.01 exhibits
- 2026-08-10 Filing 8-K filed: Item 8.01 other event; Item 9.01 exhibits
- 2026-08-06 Filing 10-Q filed
- 2026-08-06 Filing 8-K filed: Item 2.02 results of operations; Item 9.01 exhibits
- 2026-06-18 Filing 8-K filed: Item 5.07 shareholder vote
- 2026-05-12 Filing 10-Q filed
- 2026-05-12 Filing 8-K filed: Item 2.02 results of operations; Item 9.01 exhibits
- 2026-04-27 Filing ARS filed
- 2026-04-27 Filing DEFA14A filed
- 2026-04-27 Filing DEF 14A filed
- 2026-03-02 Filing S-8 filed
- 2026-03-02 Filing S-3ASR filed
- 2026-03-02 Filing 10-K filed
- 2026-03-02 Filing 8-K filed: Item 2.02 results of operations; Item 9.01 exhibits
- 2025-11-05 Filing 10-Q filed
- 2025-11-05 Filing 8-K filed: Item 2.02 results of operations; Item 9.01 exhibits
- 2025-08-11 Filing 10-Q filed
- 2025-08-11 Filing 8-K filed: Item 2.02 results of operations; Item 9.01 exhibits
- 2025-06-13 Filing 8-K filed: Item 5.07 shareholder vote
- 2025-06-04 Filing 8-K filed: Item 7.01 Regulation FD disclosure; Item 9.01 exhibits
- 2025-05-12 Filing 10-Q filed
- 2025-05-12 Filing 8-K filed: Item 2.02 results of operations; Item 9.01 exhibits
- 2025-04-29 Filing ARS filed
POSSIBLE MATCHES · GROUPED BY SOURCE8. Enforcement by agency
EPA ECHO facilities (1)
possible match: matched by name only, not merged (1)
Possible match based on name, not a shared identifier. Compare the records.
- possible matchSIONNA THERAPEUTICS · exact name match to 'Sionna Therapeutics, Inc.' (no other entity shares the name) · sx:epa:110071333461 Compare
Each record's own page holds its date and the agency document. Matched by exact name only; none of these is counted in the headline.
AS FILED · LARGEST HOLDERS10. 13F institutional holders
| Rank | Holder (13F filer) | Value held | As of | Source | Retrieved | Report |
|---|---|---|---|---|---|---|
| 1 | RA CAPITAL MANAGEMENT, L.P. | $435,722,930 | 2026-06-30 | SEC 13F filing | 2026-11-20 22:48 UTC | Report an error |
| 2 | TPG GP A, LLC | $285,713,378 | 2026-06-30 | SEC 13F filing | 2026-11-20 22:48 UTC | Report an error |
| 3 | VIKING GLOBAL INVESTORS LP | $140,556,012 | 2026-06-30 | SEC 13F filing | 2026-11-20 22:48 UTC | Report an error |
| 4 | Atlas Venture Life Science Advisors, LLC | $131,776,532 | 2026-06-30 | SEC 13F filing | 2026-11-20 22:48 UTC | Report an error |
| 5 | ORBIMED ADVISORS LLC | $112,433,029 | 2026-06-30 | SEC 13F filing | 2026-11-20 22:48 UTC | Report an error |
| 6 | ENAVATE SCIENCES GP, LLC | $109,008,540 | 2026-06-30 | SEC 13F filing | 2026-11-20 22:48 UTC | Report an error |
| 7 | ADAGE CAPITAL PARTNERS GP, L.L.C. | $70,384,000 | 2026-06-30 | SEC 13F filing | 2026-11-20 22:48 UTC | Report an error |
| 8 | BlackRock, Inc. | $64,875,089 | 2026-06-30 | SEC 13F filing | 2026-11-20 22:48 UTC | Report an error |
| 9 | JPMORGAN CHASE & CO | $64,085,673 | 2026-06-30 | SEC 13F filing | 2026-11-20 22:48 UTC | Report an error |
| 10 | JENNISON ASSOCIATES LLC | $51,562,131 | 2026-06-30 | SEC 13F filing | 2026-11-20 22:48 UTC | Report an error |
13F as filed: the holder's own report of its position value at the quarter end.
POSSIBLE MATCHES · LICENCES, PERMITS, CITY AND STATE RECORDS13. Permits and local records
2 state and city records carry this company's exact name, from 2 sources. Possible matches only.
ClinicalTrials.gov (1)
possible match: matched by name only, not merged (1)
Possible match based on name, not a shared identifier. Compare the records.
- possible matchSionna Therapeutics Inc. · exact legal name · sx:ctgov:hec359511fde178aa Compare
State licences (1)
possible match: matched by name only, not merged (1)
Possible match based on name, not a shared identifier. Compare the records.
- possible matchSIONNA THERAPEUTICS, INC. · exact legal name · sx:elic:ctcred:2593699 Compare
WHAT THIS PAGE READ
Sources
JSON · MCP · API
API and agents
The same profile as JSON: GET /company/2036042.json. The MCP server and the records API return the same data: GET /v1/record/sx:sec:0002036042. Every source URL used is listed in the file.
Get the evidence file, alerts and the API with a free key. Everything on this page stays free to read.